pharma · Oral Mucositis · Complex Cardiovascular Surgery With Cardiopulmonary Bypass
CSL Behring
CSL Behring GmbH
CSL Behring is a pharma organization headquartered in Marburg, DE. Primary therapeutic focus areas include Oral Mucositis, Complex Cardiovascular Surgery With Cardiopulmonary Bypass, Rheumatoid Arthritis, Antibody-mediat
Marburg, DE HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- Marburg, DE
- Programs
- 7
- Drugs
- 6
- Patents
- 25
Clazakizumab
Phase 3 · mab · Antibody-mediated Rejection
Clazakizumab for Antibody-mediated Rejection is a Phase 3 program (mab) at CSL Behring GmbH with 1 ClinicalTrials.gov record(s).
Internal code CSL300_3001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CSL Behring GmbH
- Phase
- Phase 3
- Modality
- mab
- Indication
- Antibody-mediated Rejection
- Status
- terminated
- Trials
- 1